» Articles » PMID: 29129775

Connecting Alzheimer's Disease to Diabetes: Underlying Mechanisms and Potential Therapeutic Targets

Overview
Specialties Neurology
Pharmacology
Date 2017 Nov 14
PMID 29129775
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a risk factor for type 2 diabetes and vice versa, and a growing body of evidence indicates that these diseases are connected both at epidemiological, clinical and molecular levels. Recent studies have begun to reveal common pathogenic mechanisms shared by AD and type 2 diabetes. Impaired neuronal insulin signaling and endoplasmic reticulum (ER) stress are present in animal models of AD, similar to observations in peripheral tissue in T2D. These findings shed light into novel diabetes-related mechanisms leading to brain dysfunction in AD. Here, we review the literature on selected mechanisms shared between these diseases and discuss how the identification of such mechanisms may lead to novel therapeutic targets in AD. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'

Citing Articles

Experimental Type 2 diabetes and lipotoxicity-associated neuroinflammation involve mitochondrial DNA-mediated cGAS/STING axis: implication of Type-1 interferon response in cognitive impairment.

Preeti K, Sood A, Fernandes V, Khan I, Khatri D, Singh S Mol Neurobiol. 2024; 61(9):6217-6244.

PMID: 38285288 DOI: 10.1007/s12035-024-03933-y.


Potential Retinal Biomarkers in Alzheimer's Disease.

Garcia-Bermudez M, Vohra R, Freude K, van Wijngaarden P, Martin K, Thomsen M Int J Mol Sci. 2023; 24(21).

PMID: 37958816 PMC: 10649108. DOI: 10.3390/ijms242115834.


Polyoxidovanadates a new therapeutic alternative for neurodegenerative and aging diseases.

Gonzalez-Cano S, Flores G, Guevara J, Morales-Medina J, Trevino S, Diaz A Neural Regen Res. 2023; 19(3):571-577.

PMID: 37721286 PMC: 10581577. DOI: 10.4103/1673-5374.380877.


Relationships Between Body Composition and Cognitive Impairment in Hospitalised Middle-Aged Type 2 Diabetic Patients.

Li Y, Liu Y, Wang J, Haghbin N, Wang X, Jiang W Diabetes Metab Syndr Obes. 2023; 16:2389-2400.

PMID: 37581116 PMC: 10423571. DOI: 10.2147/DMSO.S418111.


Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.

Pelle M, Zaffina I, Giofre F, Pujia R, Arturi F Int J Mol Sci. 2023; 24(14).

PMID: 37511061 PMC: 10379573. DOI: 10.3390/ijms241411301.